NAD+ Longevity Claims Outpace Evidence, Raising Questions of Regulatory Oversight in India

In recent months, a cadre of self‑styled wellness and longevity influencers across the Indian subcontinent have begun extolling the virtues of nicotinamide adenine dinucleotide, commonly abbreviated NAD+, asserting that its oral supplementation and intravenous infusion can arrest ageing, restore vigour, and extend human lifespan beyond current biological limits. Scientific investigation, however, remains in a nascent stage, with peer‑reviewed trials limited to small cohorts and animal models, thereby rendering the sweeping commercial promises premature, if not outright speculative, in the eyes of the nation's biomedical scholars.

The Food Safety and Standards Authority of India, the primary regulator for nutraceuticals, has issued generic guidelines permitting the sale of NAD+ preparations, yet has yet to promulgate specific safety evaluations or efficacy mandates, exposing a regulatory lacuna that commercial interests appear eager to exploit. Consumers, predominantly middle‑class professionals and aspirational retirees, are enticed by glossy advertisements promising rejuvenated metabolism and diminished cognitive decline, leading many to allocate substantial household resources toward products whose purported benefits lack corroboration by rigorous clinical data. Medical practitioners, when consulted, frequently encounter patients requesting NAD+ regimens, compelling physicians to navigate a delicate balance between respecting patient autonomy and cautioning against unverified interventions, a predicament that underscores systemic shortcomings in public health communication.

The present lacuna in statutory oversight invites scrutiny of whether the existing provisions of the Drugs and Cosmetics Act, as amended to encompass nutraceuticals, possess sufficient granularity to compel manufacturers of NAD+ formulations to furnish robust pharmacovigilance data, thereby safeguarding citizens from potential adverse events that may only surface after widespread consumption. Moreover, the apparent reliance upon self‑regulatory codes issued by industry associations, rather than a proactive adjudication by the Ministry of Health and Family Welfare, raises the prospect that policy inertia may be allowing commercial narratives to eclipse empirically derived guidance, a circumstance that could erode public confidence in the nation's health governance mechanisms. Consequently, one must inquire whether the Consumer Protection (Amendment) Act of 2020 can be invoked to compel transparency in labeling, whether the Supreme Court will entertain public interest litigation to demand pre‑market authorization for compounds promising anti‑ageing effects, and whether Parliament will contemplate a dedicated legislative framework to reconcile burgeoning wellness entrepreneurship with the imperatives of evidence‑based medical practice.

The socioeconomic dimension of the NAD+ phenomenon cannot be ignored, for while affluent urban dwellers may afford repeated infusions at private clinics, the aspirational poor, enticed by anecdotal testimonies circulating on social media, risk diverting scarce financial resources from essential health and education expenses toward unsubstantiated longevity regimens, and thereby compromising their capacity to afford preventive vaccinations and essential schooling for their children. Such a dichotomy amplifies existing fissures in access to quality healthcare, thereby prompting a re‑examination of whether the National Health Mission's equity‑oriented objectives are being undermined by market‑driven narratives that valorise bio‑hacking over proven public health interventions. Accordingly, it becomes imperative to ask whether the Union government will institute mandatory post‑marketing surveillance for NAD+ supplements, whether state health departments will allocate resources to educate the populace about the distinction between scientifically validated therapeutics and commercially embellished promises, and whether the judiciary will recognize a duty of care owed by advertisers to prevent exploitation of the elderly seeking age‑defying remedies.

Published: May 11, 2026